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Abstract
Chronic myelogenous leukemia (CML) can be controlled for years with the tyrosine kinase inhibitor imatinib but be-
cause imatinib poorly penetrates the blood-brain barrier (BBB), on occasion, the CML clone will thrive and evolve to an
accelerated phase in the resulting imatinib sanctuary within the central nervous system. In this, CML resembles glio-
blastoma in that imatinib, which otherwisemay be effective, cannot get to the tumor. Although a common street drug
of abuse, methamphetamine is Food and Drug Administration–approved and marketed as a pharmaceutical drug to
treat attention-deficit disorders. It has shown the ability to open the BBB in rodents. We have some clinical hints that it
may do so in humans as well. This short note presents three new points potentially leading to better tyrosine kinase
inhibition behind the BBB: 1) Pharmaceutical methamphetamine may have a useful role in treating both CML and
glioblastoma by allowing higher imatinib concentrations behind the BBB. 2) The old antidepressant and monoamine
oxidase inhibitor selegiline, used to treat Parkinson disease, is catabolized to methamphetamine. Selegiline, as a non-
scheduled drug, may therefore be an easier way to open the BBB, allowingmore effective chemotherapywith tyrosine
kinases. 3) Dasatinib is a tyrosine kinase inhibitor with a spectrum of inhibition only partially overlapping that of
imatinib and a mechanism of tyrosine kinase inhibition that is different from that of imatinib. The two should be addi-
tive. In addition, dasatinib crosses the BBBpoorly, and it can therefore be expected to benefit frommethamphetamine-
assisted entry.
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Prelude
“The battle is fought and decided by the quartermasters before the
shooting begins,” said Erwin Rommel, Nazi general who won many
smaller battles against much superior forces but ultimately lost all his
bigger battles by his opponents’ superior quartermasters. The quarter-
master corps supplies the tools and equipment of war to the combat
troops—ammunition, food, fuel, transport, and weapons.
Introduction
Isobe et al. [1] showed the consequences of chronic myelogenous leu-
kemia (CML) of imatinib’s poor penetration of the blood-brain barrier
(BBB). They reported a patient with CML with blast crisis limited to
the central nervous system (CNS) compartment reminiscent of simi-
lar reports of CNS blast crisis occurring in otherwise well-treated patients
on imatinib [2] or the situation seen occasionally in acute lymphoblastic
leukemia [3] where the systemic malignant clone seems absent or pro-
foundly suppressed by imatinib yet the neoplasm reappears in the
CNS. This is understandable because the cerebrospinal fluid (CSF) con-
centration of imatinib is less than 3% that of plasma in patients [1,3–
5] and mice [6]. The retention of a malignant CML clone protected
from exposure to imatinib behind the BBB, growing and evolving most
dangerously even in the systemic presence of a safe and potent drug
that would otherwise suppress it, parallels our predicament in glioblas-
toma where the cells start and finish their life course behind the BBB.
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Therefore, prognosis remains unusually poor. We require a better
quartermaster corps than we now have to win that big battle, too.
The recent article by Isobe et al. [1] points out the problem in the
context of CML that glioblastoma researchers have been wrestling
with for decades [5,7–9]. In this short note, the rationale is discussed
for using two currently marketed drugs with significant potential to
open the BBB allowing better entry of tyrosine kinases (TKs) and
therefore more effective treatment of both CML with CNS involve-
ment and glioblastoma.
Glioblastomas and TKs
Imatinib has shown good potential for antiglioblastoma activity [10–15],
but the problem, as for the patient of Isobe et al., has always been how to
get adequate imatinib levels across the BBB to themalignant tissue [5,7,8].
Flow cytometry and immunohistochemistry show ample glioblas-
toma expression of TK targets [16–18], particularly so in the stem cell
subpopulation [16–18], which should be susceptible to inhibition by
imatinib if we could get the drug in adequate amounts across the BBB
to the far-flung paucicellular extensions that remain after primary surgi-
cal resection. In vitro imatinib activity is good with growth arrest at 1 to
10 μM and cytotoxicity at 20 μM against glioblastoma cell lines [18].
Although glioblastoma are commonly said to have leaky BBBs, this
is true only for the main tumor mass and then only parts of it. The far-
flung microscopic extensions have intact BBBs [7,8].
The TK’s activities in malignancy promotion in glioblastoma [19–
21] are less clear, less well identified than the TK’s overactivity in CML
[22–24], but Src overactivity is one of them. Dasatinib is a good in-
hibitor of the specific TK BCR-ABL of CML, is clinically effective
in CML [25–27], and is a much more potent inhibitor of Src than is
imatinib [21,28,29].
Opening the BBB
Having free access to CSF and glioblastoma tissue and the normal
brain tissue surrounding the fine, microscopic extensions will greatly
advance our ability to treat both CML and glioblastoma.
Although only documented in rodents, methamphetamine has the
unusual attribute of massively disrupting the BBB for several hours
(reviewed in Kast [30,31]). First synthesized in Japan in 1893, and al-
though a common current drug of abuse [32,33], methamphetamine
is a registered and marketed pharmaceutical drug in the USA and
elsewhere (Desoxyn, Ovation Pharmaceuticals, recently purchased by
Lundbeck Pharmaceuticals) and approved to treat attention-deficit pro-
blems in people older than 12 years (full prescribing information at
http://www.lundbeckinc.com/USA/products/CNS/desoxyn). It is also
approved for weight loss in women in the United States. Clinical ex-
perience suggests that it does not work for weight loss but does work
well for relieving attention or concentration problems. For obvious rea-
sons, it should not be used for either indication.
Patients report feeling no different on pharmaceutically prescribed
methamphetamine than they do on the more commonly used methyl-
phenidate (Ritalin, Concerta, and other brand names) or dexamphetamine
(dextroamphetamine, Adderal, and other brand names).
Pharmaceutical methamphetamine has a circulating half-life of 9 to
15 hours, Cmax of 1 hour, and a US Food and Drug Administration–
approved maximum daily dose of 25 mg. Metabolism is hepatic; ex-
cretion is renal [33].
Given that rodent studies show that 64-kDa albumin can leak after
methamphetamine treatment, we might expect imatinib, 494 Da, to
do so [30,31].
We also have indirect evidence that abuse of street methamphetamine
leads to BBB opening. Street methamphetamine users have a higher
incidence of hepatitis C encephalitis than hepatitis C virus–infected
nonusers [34] and higher CNS human immunodeficiency virus titer
[35] indicating loss of BBB integrity.
Indirect Methamphetamine Delivery
The monoamine oxidase inhibitor selegiline is approved, marketed, and
used in many countries for treatment of depression (at higher doses) and
Parkinson disease (at low doses). Relevant here is that selegiline’s primary
metabolite is methamphetamine [36–38]. Clinically significant amounts
of methamphetamine are circulating in patients currently treated with
selegiline [37,38]. Is that level enough to decrease BBB integrity? This
matter requires urgent study. If selegiline-derived methamphetamine is
disrupting BBB to any significant degree, then selegiline use must stop
for all indications except potentially that of opening the BBB to allow
more effective chemotherapy for CNS-resident malignancies. Because
it is probable that selegiline catabolism to methamphetamine is primar-
ily mediated by P450 2B6 [33], inducers of 2B6 such as pentobarbital,
phenobarbital, or rifampin may enhance this process.
It may be parenthetically noted here that pentobarbital, a drug available
worldwide since the 1950s, showed in vitro evidence of antiglioblastoma
effects seemingly independent of any selegiline exposure [39].
Selegiline and methamphetamine are both chiral molecules and,
as such, have a complicated pharmacology. Dextro and levo enan-
tiomers have different pharmacological attributes. If both or only one
methamphetamine enantiomer opens, the BBB is unknown.
Imatinib + Dasatinib Cooperation
In principle, dasatinib should be additive to some degree with imatinib
on three accounts:
(a) Although they are both called TKs, dasatinib and imatinib work
by different and independent mechanisms. Imatinib binds to the
ATP binding site of susceptible TKs, preventing required dona-
tion of the high-energy phosphate. Dasatinib binds to tyrosine-
containing peptide’s recognition site on TK, preventing target
peptide binding and any consequent tyrosine phosphorylation.
Dasatinib also penetrates the BBB poorly, achieving about a tenth
of the CSF concentration compared with that of plasma [25]
and may well benefit from methamphetamine-assisted CNS entry
as well.
Ifmethamphetamine indeed can provide uswith free daily access
to the brain tissue, then Src dephosphorylation (deactivation) be-
comes possible, too [31], to augment Src inhibition by dasatinib.
(b) The arrays of different TKs that are inhibited by each are different.
Although this may not be as important for CMLwhere there is one
prominent TK, the BCR-ABL TK, it seems that there are several
overactive TKs in glioblastoma and multiple paths to activating
each, so a net casted more broadly would be potentially useful.
We have several preclinical experimental indicators that dasatinib-
inhibited TKs are important in glioblastoma growth, prominent
among them is Src [19,20,25]. Src can and does activate epidermal
growth factor receptor in the absence of the epidermal growth fac-
tor [31], and this transactivation is an important element-enhancing
growth in more than half of the glioblastomas [40].
(c) Because the two have different mechanisms by which they inhibit
TK, dasatinib/imatinib cross-resistance would be expected to de-
velop more slowly [27,41].
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It is currently unknown if there would be steric hindrance at any
given TK between dasatinib and imatinib.
Conclusions
Given glioblastoma’s reliably fatal outcome within several years of diag-
nosis, and that 1 year after diagnosis, half of all patients are dead, BBB
opening to allow higher imatinib brain tissue levels in addition to cur-
rent treatments might be rewarding. After CNS relapse, CML patients
may likewise benefit from methamphetamine-assisted opening of the
BBB to allow better TK inhibition and more effective treatment.
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